Aeglea BioTherapeutics Inc (NASDAQ:AGLE) Is Expected To Breakeven

Aeglea BioTherapeutics Inc's (NASDAQ:AGLE): Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The US$234.33m market-cap posted a loss in its most recent financial year of -US$27.24m and a latest trailing-twelve-month loss of -US$29.11m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on AGLE’s investors mind, I’ve decided to gauge market sentiment. Below I will provide a high-level summary of the industry analysts’ expectations for AGLE.

According to the industry analysts covering AGLE, breakeven is near. They anticipate the company to incur a final loss in -1, before generating positive profits of US$0 in . So, AGLE is predicted to breakeven approximately a few months from now. How fast will AGLE have to grow each year in order to reach the breakeven point by ? Working backwards from analyst estimates, it turns out that they expect the company to grow -5.09% year-on-year, on average,

I’m not going to go through company-specific developments for AGLE given that this is a high-level summary, but, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. So, periods of lower growth in the upcoming years is not out of the ordinary, particularly when a company is in a period of investment.

Before I wrap up, there’s one aspect worth mentioning. AGLE currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. AGLE currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of AGLE to cover in one brief article, but the key fundamentals for the company can all be found in one place – AGLE’s company page on Simply Wall St. I’ve also compiled a list of essential aspects you should further research:

1. Valuation: What is AGLE worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether AGLE is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Aeglea BioTherapeutics’s board and the CEO’s back ground.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.